使用LMWH和DOACs进行顺序抗凝治疗,用于肝硬化门静脉血栓症
Melis Onay1, Myriam Heilani1, Chaarvee Gulia1
1University Hospital Frankfurt Department of Medicine I Gastroenterology Hepatology, Pneumology Allergology Endocrinology Diabetology, Heidelberg, Germany.
Clinics and research in hepatology and gastroenterology
|February 25, 2026
概括
抗凝治疗改善了肝硬化患者的存活率,这些患者患有门静脉血栓症 (PVT). 连续的低分子量肝素/直接口服抗凝剂 (DOAC) 治疗可能会带来好处,而DOAC似乎对某些患者是安全的.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血管医学 血管医学
- 血栓形成研究研究
背景情况:
- 门静脉血栓塞 (PVT) 是肝硬化患者经常出现的并发症.
- 包括直接口服抗凝剂 (DOACs) 在内的最佳抗凝策略需要进一步研究.
研究的目的:
- 评估不同抗凝策略在肝硬化PVT的有效性和安全性.
- 为了比较结果,如出血,再通道,死亡率和无事件生存 (EFS).
主要方法:
- 追溯队列研究分析肝硬化和PVT患者.
- 抗凝策略的比较:低分子量肝素 (LMWH),DOACs,顺序的LMWH/DOAC,没有抗凝.
- 统计分析包括时间到事件和多变量回归模型.
主要成果:
- 与没有抗凝药相比,抗凝药显著改善了生存率.
- 在抗凝固策略之间没有发现出血或死亡率的显著差异.
- 连续的LMWH/DOAC治疗显示了改善生存率和EFS的趋势.
- DOACs没有增加出血风险;PVT复发与较高的死亡率有关.
结论:
- 抗凝药与患有PVT的肝硬化患者的更好的生存率有关.
- 在精心挑选的患者中,DOAC是安全的.
- 连续的LMWH/DOAC治疗需要对潜在的临床益处进行前性验证.
关键词:
这是一种抗凝血药物.竞争风险分析竞争风险分析考克斯的比例危险模型.直接的口服抗凝剂 直接的口服抗凝剂没有事件的生存率.细灰色的模型肝硬化是肝硬化的一种疾病.低分子量肝素是一种低分子量肝素.门静脉血栓形成的原因对生存分析的分析.更多相关视频
相关概念视频
Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis IV: Nursing Management
320
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
320
Hepatic Portal System
6.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.8K
Esophageal Varices-II: Clinical Features and Management
685
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
685


